Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.12
  • Today's Change0.04 / 0.23%
  • Shares traded20.46k
  • 1 Year change+80.97%
  • Beta0.8091
Data delayed at least 15 minutes, as of Nov 23 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Teva Pharmaceutical Industries Ltd is a Israeli-based pharmaceutical company. The Company operates through three segments: North America, Europe and International Markets. Each business segment manages entire product portfolio in its region, including generics, specialty and over-the-counter (OTC) products. In addition to these three segments, The Company has other activities, primarily the sale of active pharmaceutical ingredients (API) to third parties, certain contract manufacturing services and an out-licensing platform offering a portfolio of products to other pharmaceutical companies through its affiliate Medis.

  • Revenue in USD (TTM)16.77bn
  • Net income in USD-993.00m
  • Incorporated1944
  • Employees35.00k
  • Location
    Teva Pharmaceutical Industries Ltd124 Dvora Hanevi'a St.TEL AVIV-YAFO 6944020IsraelISR
  • Phone+972 39148213
  • Fax+972 39234050
  • Websitehttps://www.tevapharm.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Catalent Inc4.42bn-413.00m11.07bn16.90k--3.12143.752.50-2.27-2.2724.3319.570.44824.923.27261,656.80-4.190.0124-4.800.01421.8228.93-9.340.02781.930.78140.5821--2.7711.71-307.42--8.44--
Biomarin Pharmaceutical Inc2.75bn322.29m12.25bn3.40k38.652.2629.024.451.661.6614.0228.410.40460.52424.08809,411.604.740.71165.490.807978.9576.3011.712.052.62--0.0990.0015.4210.1636.51---5.74--
Incyte Corp4.08bn32.48m13.82bn2.52k512.474.36114.423.390.140.1418.7916.450.7154.235.761,614,842.000.56989.070.740411.0293.3794.970.796913.681.82--0.010.008.8714.4575.4240.41-15.06--
Royalty Pharma plc2.27bn1.15bn15.57bn89.0010.332.2721.706.872.562.563.8011.630.1337--72.1525,460,710.0010.119.5713.3012.42----75.6467.80----0.425823.475.245.582,549.50-3.8050.99--
Viatris Inc15.05bn-883.30m15.96bn38.00k--0.80638.361.06-0.7389-0.738912.5416.580.32192.234.94396,013.20-1.890.0887-2.230.106142.4940.29-5.870.28910.96152.370.443560.11-5.146.17-97.37-30.53-16.88--
Teva Pharmaceutical Industries Ltd (ADR)16.77bn-993.00m19.25bn35.00k--3.20--1.15-0.8728-0.872814.885.350.40012.054.90479,186.30-2.99-3.14-4.34-4.2951.0148.14-7.46-9.870.60564.720.7483--6.17-3.4277.15---4.17--
Biogen Inc9.61bn1.62bn23.01bn7.57k14.271.4010.162.3911.0711.0765.83112.900.340.86044.581,269,155.005.7112.537.0114.8375.5983.0416.8026.930.80394.890.27780.00-3.32-6.07-61.89-23.58-18.87--
Data as of Nov 23 2024. Currency figures normalised to Teva Pharmaceutical Industries Ltd's reporting currency: US Dollar USD

Institutional shareholders

26.73%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 30 Sep 202460.83m5.37%
Ion Asset Management (Israel) Ltd.as of 30 Sep 202436.24m3.20%
Clal Pension & Provident Funds Ltd.as of 30 Sep 202434.54m3.05%
BlackRock Fund Advisorsas of 30 Sep 202432.31m2.85%
Menora Mivtachim Insurance Ltd.as of 30 Sep 202428.84m2.55%
Lingotto Investment Management LLPas of 30 Sep 202426.50m2.34%
Migdal Insurance Co. Ltd. (Investment Portfolio)as of 30 Sep 202425.47m2.25%
Phoenix Investments House Ltd.as of 30 Sep 202422.56m1.99%
SSgA Funds Management, Inc.as of 30 Sep 202419.50m1.72%
Rubric Capital Management LPas of 30 Sep 202416.01m1.41%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.